DOMPE

Engitix specializes in developing tissue-engineered products for regenerative medicine and drug-target research, utilizing its proprietary human organ decellularization technology. The company's main focus is on liver disease, leveraging its expertise in human extracellular matrix (ECM) scaffolds and 3D spheroids to create bioartificial liver devices. Additionally, Engitix is expanding its technology applications to other organs and conditions, including pancreatic and intestinal diseases. By creating tissue-specific and disease-specific ECMs, Engitix aims to enhance the drug discovery process in fibrosis and oncology, ultimately improving the quality of life for patients with advanced fibrosis and solid tumors.

mPharma is a healthcare company focused on enhancing access to affordable medications in emerging markets. Founded in 2013 by Gregory Rockson, Daniel Shoukimas, and James Finucane, mPharma collaborates with drug manufacturers, insurance providers, financial institutions, and governments to streamline the delivery of prescription drugs to consumers. The company offers a pharmaceutical data analytics platform that assists pharmacies in managing their inventory, prescribing medications, and reporting adverse drug reactions. By ensuring that high-quality chronic disease medications are consistently available at sustainable prices, mPharma aims to improve health outcomes for patients, doctors, and pharmacists alike.

Philogen is a Swiss-Italian biotechnology company founded in 1996 that specializes in the development of innovative biopharmaceuticals for treating angiogenesis-related disorders, including cancer and chronic inflammatory diseases. The company has made significant advancements in isolating and engineering human monoclonal antibodies that target angiogenesis, demonstrating their efficacy in both animal models and clinical trials. Philogen's pipeline includes several promising anti-cancer antibody derivatives and an antibody derivative for rheumatoid arthritis, with two registrational studies currently in planning. The company operates through its Zurich-based research and development unit, Philochem, which identifies and isolates candidate products, while its manufacturing facility in Siena, Italy, adheres to GMP standards for pharmaceutical production. Philogen has established collaborations with major pharmaceutical companies and holds a diverse portfolio of international patents, generating revenue through various activities. The company's operations extend across the European Union, Switzerland, and the United States.